Mitral Valve Repair Versus Replacement in Simultaneous Mitral and Aortic Valve Surgery for Rheumatic Disease
|
|
- Gyles Robertson
- 6 years ago
- Views:
Transcription
1 Mitral Valve Repair Versus Replacement in Simultaneous Mitral and Aortic Valve Surgery for Rheumatic Disease Kenji Kuwaki, MD, PhD, Nobuyoshi Kawaharada, MD, PhD, Kiyofumi Morishita, MD, PhD, Tetsuya Koyanagi, MD, Hisayoshi Osawa, MD, PhD, Toshiyuki Maeda, MD, and Tetsuya Higami, MD, PhD Department of Thoracic and Cardiovascular Surgery, Sapporo Medical University School of Medicine, Sapporo, Japan Background. The purpose of this study was to compare the late results of combined mitral valve repair and aortic valve replacement with double valve replacement for patients with rheumatic heart disease. Methods. From 1981 to 2003, 128 patients underwent aortic valve replacement with either mitral valve repair (n 47) or mitral valve replacement (n 81) for rheumatic disease. Mean follow-up was years. Results. Rates of actuarial freedom from cardiac-related death (81.4% versus 75.9% at 12 years; p 0.60), thromboembolism (79.8% versus 85.1% at 12 years; p 0.78), and bleeding (97.3% versus 95.7% at 12 years; p 0.77) were similar in both combined mitral valve repair and aortic valve replacement and double valve replacement. However, freedom from mitral valve reoperation was significantly lower in combined mitral valve repair and aortic valve replacement compared with double valve replacement (52.6% versus 76.8% at 12 years; p 0.002). Mitral valve repair (p 0.002) and mitral bioprosthesis (p ) were independent risk factors for mitral valve reoperation. Conclusions. Potential advantages of preserving, rather than replacing, the native mitral valve, such as better cardiac survival or fewer thromboembolic complications, were not identified in combined mitral valve repair and aortic valve replacement compared with double valve replacement for patients with rheumatic disease. Indeed, combined mitral valve repair and aortic valve replacement was associated with a significantly higher incidence of mitral valve reoperation. Therefore, in double valve surgery for rheumatic disease, mitral valve repair should be limited to the correction of mitral valve lesions only when excellent durability can be expected. (Ann Thorac Surg 2007;83:558 63) 2007 by The Society of Thoracic Surgeons Whether mitral valve repair (MVP) or replacement (MVR) in simultaneous mitral and aortic valve surgery will be associated with a better result remains uncertain. No specific recommendations for treatment, including surgical strategy, of multiple valve disease has been developed in the American College of Cardiology/ American Heart Association practice guidelines for the management of patients with valvular heart disease because there are remarkably few data relating to mixed valve disease [1]. Some groups [2, 3] have recommended MVP plus aortic valve replacement (AVR) as the preferred strategy in mixed patient populations with double valve disease, whenever MVP is possible. However, other groups have advocated double valve replacement (DVR) as the standard procedure [4, 5]. Among several causes of double valve disease, rheumatic disease remains the predominant cause even in reports from Western countries [2, 6, 7]. The aims of this study were to compare the late results of Accepted for publication Aug 9, Address correspondence to Dr Kuwaki, Department of Thoracic and Cardiovascular Surgery, Sapporo Medical University School of Medicine, South 1, West 16, Chuo-Ku, Sapporo, , Japan; kuwaki@ sapmed.ac.jp. MVP AVR with those of DVR in patients with rheumatic disease, and to identify the independent clinical predictors of late adverse events in all patients. Patients and Methods Patients Between 1981 and 2003, 128 patients underwent simultaneous mitral and aortic valve surgery for rheumatic disease at Sapporo Medical University Hospital. This cohort excluded 26 patients who underwent DVR involving re-mvr after failure of a mitral valve prosthesis implanted previously. This study was approved by the Medical Ethics Committee in Sapporo Medical University. An MVP AVR was performed in 47 patients (37%), and a DVR was performed in 81 patients (63%). Baseline preoperative and intraoperative characteristics of the study cohort are presented in Table 1. Mean follow-up time for MVP AVR and DVR was (range, 2 months to 17 years) and years (range, 3 months to 19 years), respectively (no significant difference). The cumulative follow-up for MVP AVR and DVR was 372 and 653 patient-years, respectively. Closing interval of follow-up was between January 2004 and November 2007 by The Society of Thoracic Surgeons /07/$32.00 Published by Elsevier Inc doi: /j.athoracsur
2 Ann Thorac Surg KUWAKI ET AL 2007;83: MITRAL VALVE REPAIR VERSUS REPLACEMENT IN DOUBLE VALVE SURGERY 559 Table 1. Baseline Preoperative and Intraoperative Characteristics MVP AVR DVR N Mean age (y) a Male gender Preop NYHA IV Previous MV repair a Sinus rhythm CI 2, L min 1 m Mitral stenosis a Mitral regurgitation MSR a SevereTR (requir TAP) a Renal failure (Cr 2) DM History of stroke or TIA AXT 180 min a CPB 240 min a AVR aortic valve replacement; AXT aortic cross-clamp time; CI cardiac index; CPB cardiopulmonary bypass time; Cr creatinine; DM diabetes mellitus; DVR double valve replacement; MSR mixed mitral valve stenosis and regurgitation; MV mitral valve; MVP mitral valve repair; NYHA Yew York Heart Association functional class; Preop preoperative; TAP tricuspid valve annuloplasty; TIA transient ischemic attack; TR tricuspid valve regurgitation Seven patients (3 in MVP AVR and 4 in DVR) were lost to follow-up. The completeness of follow-up was 95%. Complications were defined in accordance with the published guidelines for reporting morbidity and mortality after cardiac valvular operation [8]. Operative Procedures All procedures were carried out through a median sternotomy using cardiopulmonary bypass with moderate systemic hypothermia (27 30 C). Myocardial protection was achieved with antegrade or combined antegrade and retrograde cold blood cardioplegia with topical ice-slush cooling to protect the myocardium during cardiac arrest. The mitral valve prostheses included 66 mechanical valves (DuroMedics, n 23; CarboMedics, n 19; St. Jude Medical, n 16; Bicarbon, n 4; MIRA, n 4) and 15 biological valves (Liotta, n 13; Mitroflow, n 1; Carpentier-Edwards, n 1). Although chordal-sparing MVR was carried out in the majority of patients, we were unable to identify with certainty which patients underwent chordal-sparing MVR from the operative records. Mitral valve repair procedures consisted of open mitral commissurotomy in 44 patients and commissural annuloplasty in 5. Concomitant procedures included DeVega tricuspid annuloplasty in 41 patients, Maze in 7, and coronary artery bypass grafting in 3. Aortic valve prostheses included 128 mechanical valves (Omniscience, n 44; Omnicarbon, n 32; CarboMedics, n 28; St. Jude Medical, n 17; Bicarbon, n 4; ATS, n 2; Lillehei Kaster, n 1). Postoperative Anticoagulation Anticoagulation with warfarin potassium was commenced 2 to 3 days after the operation. Between 1981 and 1997, a thrombo-test (TT) was mainly used for monitoring warfarin anticoagulation therapy; the target level of TT was between 10% and 25%, which corresponded to an international normalized ratio for prothrombin time (INR) of 1.5 to 3.0. Since 1998, the INR has mainly been used to control warfarin anticoagulation; the target level of INR was between 2.0 and 3.0 for MVP AVR patients and between 2.5 and 3.0 for DVR patients. Statistical Analysis Statistical analysis was performed using StatView 5.0 software (Abacus Concept Inc, Berkeley, CA). Timedependent events were evaluated using a univariate analysis of log-rank test and a stepwise Cox proportional hazards multivariable model. s with a probability value less than 0.2 on univariate analysis were then entered into a multivariable analysis. A probability value less than 0.05 was considered statistically significant. s examined by multivariable analysis to identify the independent risk factors for late adverse events in all patients included the following: age older than 55 years, sex, New York Heart Association functional class IV, previous MVP, preoperative stroke or transient ischemic attack, mitral valve regurgitation (MR), mitral valve stenosis (MS), mixed MS and MR, concomitant tricuspid valve procedure, atrial fibrillation, preoperative cardiac index less than 2.0 L min 1 m 2, MVP AVR, DVR, bioprosthetic MVR, years of operation, renal dysfunction (serum creatinine 2.0 mg/dl), diabetes mellitus, aortic cross-clamp time greater than 180 minutes, and cardiopulmonary bypass time greater than 240 minutes. Survival and event-free curves were described using the Kaplan Meier method. Probability estimates were expressed as mean standard error of the mean, and continuous data were expressed as mean standard deviation. We also performed a propensity score analysis to examine the potential selection bias associated with the choice of mitral valve procedure (MVP versus MVR), and to evaluate the effect of the potential bias on late outcome. s examined by logistic regression analysis in terms of selection of the surgical procedure on the mitral valve (MVP versus MVR) included the following: age older than 55 years, preoperative New York Heart Association class IV, previous MVP, preoperative stroke or transient ischemic attack, MR, MS, mixed MS and MR, concomitant tricuspid valve procedure, atrial fibrillation, preoperative cardiac index less than 2.0 L min 1 m 2, years of operation ( ), renal dysfunction (serum creatinine 2.0 mg/dl), and diabetes mellitus. The significant independent predictors associated with the surgical procedure on the mitral valve (MVP versus MVR) identified by multivariable logistic regression were previous history of MVP (which was associated with MVR), age older than 55 years at operation (which was associated with MVR), and mixed MS and MR (which
3 560 KUWAKI ET AL Ann Thorac Surg MITRAL VALVE REPAIR VERSUS REPLACEMENT IN DOUBLE VALVE SURGERY 2007;83: Table 2. Independent Predictors for the Surgical Procedure (Repair Versus Replacement) on the Mitral Valve Logistic Coefficient SE Previous history of mitral a valve repair Age more than 55 years a Mixed mitral valve stenosis a and regurgitation C-statistics 0.79 SE standard error. was associated with MVR; Table 2). C-statistics in this model was 0.79 (Table 2). Propensity score was used for the multivariable analysis for adjustment of a potential selection bias of a surgical procedure on the mitral valve. Results Early Mortality Early death was defined as death occurring within 30 days of surgery or as an in-hospital death at any time after surgery. Early mortality was 6.3% in MVP AVR and 6.1% in DVR. The causes of early deaths in MVP AVR included low cardiac output in 3 patients, and those in DVR included gastrointestinal bleeding, left ventricular rupture, cerebral hemorrhage, cerebral infarction, and arrhythmia in 1 patient each. Left ventricular rupture occurred in a 68-year-old woman who underwent DVR for mixed rheumatic mitral (mixed MS and MR) and aortic valve disease (aortic stenosis). The patient was weaned from cardiopulmonary bypass uneventfully, but severe bleeding occurred from the back of the heart and was identified from the atrioventricular groove in the posterior wall of the left ventricle. A major attempt was Table 3. Independent Predictors for Cardiac-Related Deaths Univariate Analysis Multivariable Analysis Hazard Ratio 95% CI Male sex NYHA class IV a a Propensity score 0.82 CI confidence interval; functional class. NYHA New York Heart Association made to repair the rupture, but the bleeding was not controlled and the patient eventually died. Late Mortality and Cardiac-Related Death Late death occurred in 6 patients (1.6%/patient-year) in MVP-AVR and 19 (2.9%/patient-year) in DVR. In operative survivors, the actuarial overall survival rates at 12 years in MVP AVR and in DVR were 78.6% 8.6% and 68.4% 7.1%, respectively (no significant difference, p 0.23). The causes of late deaths in MVP AVR were cardiac-related in 5 patients and malignancy in 1, and those in DVR were cardiac-related in 14 patients, malignancy in 3, aortic aneurysm in 1, and pneumonia in 1. Cardiac-related deaths in MVP AVR included early death after repeat heart valve operation in 2 patients, cerebral infarction in 1, and cerebral bleeding and unknown in 1 patient each, and those in DVR included cardiac failure in 6 patients, sudden death in 3, early death after repeat heart valve operation in 3, and cerebral infarction in 2. Actuarial freedom from cardiac-related death at 12 years in MVP AVR and in DVR was 81.4% 8.2% and 75.9% 7.0%, respectively (no significant difference, p 0.60; Fig 1). Preoperative New York Heart Association functional class IV was identified by multi- Fig 1. Freedom from cardiac-related death in mitral valve repair plus aortic valve replacement (MVP AVR; solid line) and double valve replacement (DVR; dashed line) patients. No statistically significant difference was seen between the two groups. Fig 2. Freedom from mitral valve reoperation in mitral valve repair plus aortic valve replacement (MVP AVR; solid line) and double valve replacement (DVR; dashed line) patients. A statistically significant difference (52% versus 76% at 12 years; p 0.002) was seen between the two groups.
4 Ann Thorac Surg KUWAKI ET AL 2007;83: MITRAL VALVE REPAIR VERSUS REPLACEMENT IN DOUBLE VALVE SURGERY 561 Table 4. Independent Predictors for Mitral Valve Reoperation Univariate Analysis Multivariable Analysis Hazard Ratio 95% CI Male gender 0.02 a Previous MVP Concomitant 0.04 a tricuspid procedure Cardiac index L/min/m 2 MVP AVR a a Bioprosthetic MVR a a Propensity score 0.15 AVR aortic valve replacement; CI confidence interval; MVP mitral valve repair; MVR mitral valve replacement. variable analysis as an independent predictor of cardiacrelated deaths (p 0.009; 95% confidence interval, 1.4 to 11.6; hazard ratio, 4.0; Table 3). Mitral Valve Reoperation Twenty-one patients (5.65%/patient-year) in MVP AVR required mitral valve reoperation. At reoperation, all 21 patients underwent MVR. Progression of rheumatic disease in the repaired mitral valve was the reason for reoperation in all patients except for 1 patient who required MVR because of MR 2 months after open mitral commissurotomy. Repair failure would be the reason for MR in this patient. Mitral valve lesions in 20 patients at reoperation were mitral valve restenosis in 19 patients and combined mitral valve restenosis and regurgitation in 1. Twelve patients (1.83%/patient-year) in the DVR group required mitral valve reoperation. Primary tissue Fig 3. Freedom from thromboembolism in mitral valve repair plus aortic valve replacement (MVP AVR; solid line) and double valve replacement (DVR; dashed line) patients. No statistically significant difference was seen between the two groups. Table 5. Independent Predictors for Combined Thromboembolic and Bleeding Events Univariate Analysis Multivariable Analysis Hazard Ratio 95% CI Age 55 years old Male sex Cardiac index L min 1 m 2 Propensity score 0.71 CI confidence interval. failure in the mitral bioprosthesis was the reason for reoperation in 10 patients, and thrombosis and pannus formation on a mechanical mitral prosthesis were reported in 1 patient each. All patients underwent repeat MVR with a mechanical prosthesis. Actuarial freedom from mitral valve reoperation in MVP AVR was significantly lower than that in DVR (52.6% 9.2% versus 76.8% 6.1% at 12 years; p 0.002; Fig 2). The surgical procedures of MVP AVR (p 0.002; 95% confidence interval, 1.4 to 5.9; hazard ratio, 2.9) and mitral bioprosthesis (p ; 95% confidence interval, 4.5 to 24.1; hazard ratio, 10.3) were identified by multivariable analysis as independent predictors of mitral valve reoperation (Table 4). The mortality of mitral valve reoperation in MVP AVR and DVR was 4.7% (1 of 21) and 0% (0 of 12), respectively. Thromboembolism and Bleeding There were 5 thromboembolic events (1.34%/patientyear) in MVP AVR and 10 (1.53%/patient-year) in DVR. Thromboembolic events in MVP AVR included cerebral infarction in 2 patients, transient ischemic attack in 2, and acute occlusion of a peripheral artery in 1, and those in DVR included cerebral infarction in 6, transient ischemic attack in 2, acute occlusion of a peripheral artery in 1, and thrombosis of a mechanical mitral prosthesis in 1. Actuarial freedom from thromboembolic events at 12 years in MVP AVR and in DVR was 79.8% 8.8%/ patient-year and 85.1% 5.8%/patient-year, respectively (no significant difference, p 0.78; Fig 3). Bleeding events requiring hospitalization occurred in 1 patient (0.27%/patient-year) in MVP AVR and 3 (0.46%/patient-year) in DVR. Bleeding events in MVP AVR included intracranial hemorrhage in 1 patient and those in DVR included intracranial hemorrhage in 2 patients and hemoptysis associated with pneumonia in 1. Actuarial freedom from bleeding events at 12 years in MVP AVR and in DVR was 97.3% 2.7%/patient-year and 95.7% 4.3%/patient-year, respectively (no significant difference, p 0.77). These excellent results in terms of bleeding complication in both MVP AVR and DVR might be explained by the relatively lower target level of INR in our series. Combined thromboembolic and bleeding events occurred in 6 patients in MVP AVR (1.61%/patient-year)
5 562 KUWAKI ET AL Ann Thorac Surg MITRAL VALVE REPAIR VERSUS REPLACEMENT IN DOUBLE VALVE SURGERY 2007;83: and 13 in DVR (1.99%/patient-year). No independent predictor for combined thromboembolic and bleeding events was identified in this study (Table 5). Comment The present study demonstrated that MVP AVR was associated with similar long-term survival, bleeding, and thromboembolic complications when compared with DVR in patients with rheumatic double valve disease. However, MVP AVR resulted in a significantly higher percentage of patients who required late mitral valve reoperation because of progression of underlying rheumatic mitral valve disease. Survival In the present study of double valve surgery for rheumatic valve disease, no survival advantage of MVP AVR over DVR was seen; the survival rate at 12 years from cardiac-related death was 81.4% and 75.9% for MVP AVR and DVR, respectively (p 0.60). Previous reports comparing MVP AVR and DVR in mixed patient populations also demonstrated no statistically significant difference in survival between these procedures [4 6]. These previous authors documented 10-year survival rates of 64% to 92% after MVP AVR and 87% to 90% after DVR. Yau and colleagues [9] found that in patients with isolated rheumatic mitral disease, better late cardiac survival was independently predicted by MVP than by MVR. They demonstrated that MVR with a mechanical prosthesis minimized reoperation, but limited survival and increased thromboembolic complications. The poorest cardiac survival in patients who had undergone MVR with a mechanical valve was attributed largely to thromboembolic events and the bleeding complications of long-term anticoagulation. However, in double valve surgery in relatively young patients with rheumatic disease, a mechanical valve is likely to be chosen for aortic valve replacement, and therefore long-term anticoagulation is necessary even in patients who undergo reparative mitral valve surgery. In the present series, all patients in both the DVR and MVP AVR groups received a mechanical valve in the aortic position and thus required long-term anticoagulation. This might be a reason for the lack of difference between MVP AVR and DVR in terms of late cardiac survival in this study. Mitral Valve Reoperation Our study demonstrated that the durability of MVP was significantly inferior to that of MVR in double valve surgery. Actuarial freedom from mitral valve reoperation at 12 years was 52.6% and 76.8% in MVP AVR and DVR, respectively (p 0.002). Rheumatic mitral disease is well known to be associated with inferior durability of MVP [2, 4, 5, 9 14]. After repair of a rheumatic mitral valve, actuarial freedom from mitral valve reoperation at 10 years has been reported to be 46% to 89% [2, 4, 5, 9 11]. Even with the inferior durability of MVP, many authors have recommended MVP for isolated rheumatic mitral disease when technically feasible because of better cardiac survival and fewer thromboembolic complications when compared with MVR [9, 11, 12]. Moreover, Yau and associates [9] concluded that mitral valve reoperation did not carry a demonstrably increased risk of death as they performed reoperation without mortality in 23 patients after initial MVP for isolated rheumatic mitral disease. In the present study, 21 of 47 patients in the MVP AVR group required mitral valve reoperation, and the operative mortality for these 21 patients was 4.7% (1 of 21). This mortality is acceptable considering the high risk of these 19 patients who had double valve disease, but it is a relatively high mortality. In addition, no significant advantages of MVP AVR over DVR with regard to cardiac survival and thromboembolic complications, both of which were reported to be advantages of MVP over MVR in the previous studies for isolated rheumatic mitral disease, were seen in our series. Several risk factors for late mitral valve failure after MVP in rheumatic disease, such as mixed rheumatic MS and MR, leaflet calcification, or severe subvalvular disease, have been identified [9, 15, 16]. Mitral valves with these lesions should probably be replaced instead of repaired in double valve surgery, and MVP should be limited to lesions in which excellent durability of the repair can be expected. Thromboembolism and Bleeding With regard to both thromboembolic and bleeding complications, we did not note any statistical advantage of MVP AVR over DVR. Similar results have been demonstrated in most previous studies [4 6] in double valve surgery. The lack of the need for warfarin anticoagulation is a major advantage of MVP, unless the patient has atrial fibrillation. A lower incidence of hemorrhage and thromboembolic complications after MVP, compared with MVR, for isolated mitral valve disease has been reported previously [9]. However, in the present study, all MVP AVR patients required lifelong warfarin anticoagulation because of the presence of a mechanical prosthesis in the aortic position, even when the mitral valve had been preserved by a repair technique. All DVR patients also required warfarin anticoagulation because of the insertion of at least one mechanical valve. Therefore, there was no difference between MVP AVR and DVR in terms of the need for lifelong anticoagulation. This could be a major reason for the lack of any significant advantage of MVP AVR over DVR with regard to embolic and bleeding complications. Study Limitations The present study was not randomized, and therefore a propensity score was incorporated into the multivariable analysis to reduce bias in comparing outcomes after MVP AVR and DVR. However, it is possible that significant bias may still exist by unmeasured variables. For example, in most patients we could not precisely quantify the severity of the rheumatic mitral valve lesion from either
6 Ann Thorac Surg KUWAKI ET AL 2007;83: MITRAL VALVE REPAIR VERSUS REPLACEMENT IN DOUBLE VALVE SURGERY 563 preoperative echocardiographic data or operative records (eg, severity of calcification in leaflets or annulus, degree of annular dilatation, number of chordae affected), which might have influenced treatment choice. Another limitation is the small number of patients in the study, which might be reasons why this study was unable to demonstrate advantages of survival and thromboembolic complications of MVP AVR over DVR in double valve surgery. Conclusions Similar results with regard to late morbidity and mortality were seen between MVP AVR and DVR patients, except for the need for mitral valve reoperation. Compared with DVR, MVP AVR was associated with higher incidence of mitral valve reoperation that was related to progression of the rheumatic mitral lesion. Potential advantages of MVP over MVR, such as improved cardiac survival and fewer thromboembolic events, were not identified. Therefore, in double valve surgery for rheumatic disease, MVP should be performed only in a highly selected group of patients in whom excellent durability of the repaired mitral valve can be expected. Patients with pliable mitral leaflets without subvalvular disease should be good candidates for MVP in double valve surgery. However, moderately or severely deteriorated mitral valves, such as those with leaflet calcification, thickened leaflets, or mitral valves associated with severe subvalvular disease, should probably be replaced. References 1. Bonow RO, Carabello B, de Leon AC Jr, et al. Guidelines for the management of patients with valvular heart disease. Executive summary: a report of the American College Of Cardiology/American Heart Association Task Force in Practice Guidelines (Committee on Management of Patients With Valvular Heart Disease). Circulation 1998;98: Gillinov AM, Blackstone EH, Cosgrove DM III, et al. Mitral valve repair with aortic valve replacement is superior to double valve replacement. J Thorac Cardiovasc Surg 2003;125: Szentpetery S, Rich JB, Azar H, Newton JR, Tenzer MM. Mitral valve repair combined with aortic valve replacement. J Heart Valve Dis 1997;6: Hamamoto M, Bando K, Kobayashi J, et al. Durability and outcome of aortic valve replacement with mitral valve repair versus double valve replacement. Ann Thorac Surg 2003;75: Grossi EA, Galloway AC, Miller JS, et al. Valve repair versus replacement for mitral insufficiency: when is a mechanical valve still indicated? J Thorac Cardiovasc Surg 1998;115: Mueller XM, Tevaearai HT, Stumpe F, et al. Long-term results of mitral-aortic valve operations. J Thorac Cardiovasc Surg 1998;115: Turina J, Stark T, Seifert B, Turina M. Predictors of the long-term outcome after combined aortic and mitral valve surgery. Circulation 1999;100(Supple 2):II Edmunds LH Jr, Clark RE, Cohn LH, Grunkemeier GL, Miller DC, Weisel RD. Guidelines for reporting morbidity and mortality after cardiac valvular operations. Ann Thorac Surg 1999;62: Yau TM, Farag EL, Ghoneimi YA, Armstrong S, Ivanov J, David TE. Mitral valve repair and replacement for rheumatic disease. J Thorac Cardiovasc Surg 2000;119: Deloche A, Jebara VA, Relland JYM, et al. Valve repair with Carpentier technique. The second decade. J Thorac Cardiovasc Surg 1990;99: Chauvaud S, Fuzellier JF, Berrebi A, Deloche A, Fabiani JN, Carpentier A. Long-term (29 years) results of reconstructive surgery in rheumatic mitral valve insufficiency. Circulation 2001;104(Suppl 1):I Mavioglu I, Dogan OV, Ozeren M, Dolgun A, Yucel E. Valve repair for rheumatic mitral disease. J Heart Valve Dis 2001; 10: Fernandez J, Joyce DH, Hirschfeld K, et al. Factors affecting mitral valve reoperation in 317 survivors after mitral valve reconstruction. Ann Thorac Surg 1992;54: Gillinov AM, Cosgrove DM, Lytle BM, et al. Reoperation for failure of mitral valve failure. J Thorac Cardiovasc Surg 1997;113: Detter C, Fishlein T, Feldmeier C, Nollert G, Reichenspurner H, Reichart B. Mitral commissurotomy, a technique outdated? Long-term follow-up over a period of 35 years. Ann Thorac SUrg 1999;68: Choudhary SK, Dhareshwar J, Bovil A, Airan B, Kumar AS. Open mitral commissurotomy in the current era: indications, technique, and results. Ann Thorac Surg 2003;75:41 6.
Durability and Outcome of Aortic Valve Replacement With Mitral Valve Repair Versus Double Valve Replacement
Durability and Outcome of Aortic Valve Replacement With Mitral Valve Repair Versus Double Valve Replacement Masaki Hamamoto, MD, Ko Bando, MD, Junjiro Kobayashi, MD, Toshihiko Satoh, MD, MPH, Yoshikado
More information16 YEAR RESULTS Carpentier-Edwards PERIMOUNT Mitral Pericardial Bioprosthesis, Model 6900
CLINICAL COMMUNIQUé 6 YEAR RESULTS Carpentier-Edwards PERIMOUNT Mitral Pericardial Bioprosthesis, Model 69 The Carpentier-Edwards PERIMOUNT Mitral Pericardial Valve, Model 69, was introduced into clinical
More informationPresenter Disclosure. Patrick O. Myers, M.D. No Relationships to Disclose
Presenter Disclosure Patrick O. Myers, M.D. No Relationships to Disclose Aortic Valve Repair by Cusp Extension for Rheumatic Aortic Insufficiency in Children Long term Results and Impact of Extension Material
More informationCLINICAL COMMUNIQUE 16 YEAR RESULTS
CLINICAL COMMUNIQUE 6 YEAR RESULTS Carpentier-Edwards PERIMOUNT Mitral Pericardial Bioprosthesis, Model 6900 Introduction The Carpentier-Edwards PERIMOUNT Mitral Pericardial Valve, Model 6900, was introduced
More informationOutcomes of Mitral Valve Repair for Mitral Regurgitation Due to Degenerative Disease
Outcomes of Mitral Valve Repair for Mitral Regurgitation Due to Degenerative Disease TIRONE E. DAVID, MD ; SEMIN THORAC CARDIOVASC SURG 19:116-120c 2007 ELSEVIER INC. PRESENTED BY INTERN 許士盟 Mitral valve
More informationMitral valve repair is the procedure of choice in SURGERY FOR ACQUIRED CARDIOVASCULAR DISEASE
SURGERY FOR ACQUIRED CARDIOVASCULAR DISEASE MITRAL VALVE REPAIR AND REPLACEMENT FOR RHEUMATIC DISEASE Terrence M. Yau, MD, MSc Yasser A. Farag El-Ghoneimi, MD Susan Armstrong, MSc Joan Ivanov, MSc Tirone
More informationCarpentier-Edwards Pericardial Valve in the Aortic Position: 25-Years Experience
SURGERY: The Annals of Thoracic Surgery CME Program is located online at http://www.annalsthoracicsurgery.org/cme/ home. To take the CME activity related to this article, you must have either an STS member
More informationIschemic mitral valve reconstruction and replacement: Comparison of long-term survival and complications
Surgery for Acquired Cardiovascular Disease Ischemic mitral valve reconstruction and replacement: Comparison of long-term survival and complications Eugene A. Grossi, MD Judith D. Goldberg, ScD Angelo
More informationHani K. Najm MD, Msc, FRCSC FACC, FESC President Saudi Society for Cardiac Surgeons Associate Professor of Cardiothoracic Surgery King Abdulaziz
Hani K. Najm MD, Msc, FRCSC FACC, FESC President Saudi Society for Cardiac Surgeons Associate Professor of Cardiothoracic Surgery King Abdulaziz Cardiac Centre Riyadh, Saudi Arabia Decision process for
More informationSurgery for Valvular Heart Disease. Very Long-Term Survival and Durability of Mitral Valve Repair for Mitral Valve Prolapse
Surgery for Valvular Heart Disease Very Long-Term Survival and Durability of Mitral Valve Repair for Mitral Valve Prolapse Dania Mohty, MD; Thomas A. Orszulak, MD; Hartzell V. Schaff, MD; Jean-Francois
More informationORIGINAL PAPER. The long-term results and changing patterns of biological valves at the mitral position in contemporary practice in Japan
Nagoya J. Med. Sci. 78. 369 ~ 376, 2016 doi:10.18999/nagjms.78.4.369 ORIGINAL PAPER The long-term results and changing patterns of biological valves at the mitral position in contemporary practice in Japan
More informationLong-term results (22 years) of the Ross Operation a single institutional experience
Long-term results (22 years) of the Ross Operation a single institutional experience Authors: Costa FDA, Schnorr GM, Veloso M,Calixto A, Colatusso D, Balbi EM, Torres R, Ferreira ADA, Colatusso C Department
More information15-Year Comparison of Supra-Annular Porcine and PERIMOUNT Aortic Bioprostheses
ORIGINAL CONTRIBUTION 15-Year Comparison of Supra-Annular Porcine and PERIMOUNT Aortic Bioprostheses WR Eric Jamieson, MD, Eva Germann, MSc, Michel R Aupart, MD 1, Paul H Neville, MD 1, Michel A Marchand,
More informationHani K. Najm MD, Msc, FRCSC, FRCS (Glasgow), FACC, FESC President of Saudi Heart Association King Abdulaziz Cardiac Centre Riyadh, Saudi Arabia.
Hani K. Najm MD, Msc, FRCSC, FRCS (Glasgow), FACC, FESC President of Saudi Heart Association King Abdulaziz Cardiac Centre Riyadh, Saudi Arabia. Decision process for Management of any valve Timing Feasibility
More informationThe operative mortality rate after redo valvular operations
Clinical Outcomes of Redo Valvular Operations: A 20-Year Experience Naoto Fukunaga, MD, Yukikatsu Okada, MD, Yasunobu Konishi, MD, Takashi Murashita, MD, Mitsuru Yuzaki, MD, Yu Shomura, MD, Hiroshi Fujiwara,
More informationUpdate on Oral Anticoagulation for Mechanical Heart Valves
Update on Oral Anticoagulation for Mechanical Heart Valves Douglas C. Anderson, Pharm.D., D.Ph. Professor and Chair Dept. of Pharmacy Practice Cedarville University School of Pharmacy OHIO SOCIETY OF HEALTH-SYSTEM
More informationLong term outcomes of posterior leaflet folding valvuloplasty for mitral valve regurgitation
Featured Article Long term outcomes of posterior leaflet folding valvuloplasty for mitral valve regurgitation Igor Gosev 1, Maroun Yammine 1, Marzia Leacche 1, Siobhan McGurk 1, Vladimir Ivkovic 1, Michael
More informationThe St. Jude Medical Biocor Bioprosthesis
The St. Jude Medical Biocor Bioprosthesis Clinical Evidence of Long-term Durability Long-term Biocor Experience A Review and Comparative Assessment Long-term Biocor Stented Tissue Valve Studies Twenty-year
More informationTHE IMPACT OF AGE, CORONARY ARTERY DISEASE, AND CARDIAC COMORBIDITY ON LATE SURVIVAL AFTER BIOPROSTHETIC AORTIC VALVE REPLACEMENT
THE IMPACT OF AGE, CORONARY ARTERY DISEASE, AND CARDIAC COMORBIDITY ON LATE SURVIVAL AFTER BIOPROSTHETIC AORTIC VALVE REPLACEMENT Gideon Cohen, MD Tirone E. David, MD Joan Ivanov, MSc Sue Armstrong, MSc
More informationKey words: Rheumatic heart disease, Congestive heart failure, Pulmonary hypertension, Mitral valve surgery, Maze procedure, Atrial fibrillation
Midterm Outcomes of Rheumatic Mitral Repair Versus Replacement Yao-Chang WANG, 1,2 MD, Feng-Chun TSAI, 1 MD, Jaw-Ji CHU, 1 MD, and Pyng-Jing LIN, 1 MD SUMMARY Mitral repair is feasible for patients with
More informationThe use of mitral valve (MV) repair to correct mitral
Outcomes and Long-Term Survival for Patients Undergoing Repair Versus Effect of Age and Concomitant Coronary Artery Bypass Grafting Vinod H. Thourani, MD; William S. Weintraub, MD; Robert A. Guyton, MD;
More informationDoes Patient-Prosthesis Mismatch Affect Long-term Results after Mitral Valve Replacement?
Original Article Does Patient-Prosthesis Mismatch Affect Long-term Results after Mitral Valve Replacement? Hiroaki Sakamoto, MD, PhD, and Yasunori Watanabe, MD, PhD Background: Recently, some articles
More informationA Surgeon s Perspective Guidelines for the Management of Patients with Valvular Heart Disease Adapted from the 2006 ACC/AHA Guideline Revision
A Surgeon s Perspective Guidelines for the Management of Patients with Valvular Heart Disease Adapted from the 2006 ACC/AHA Guideline Revision Prof. Pino Fundarò, MD Niguarda Hospital Milan, Italy Introduction
More informationAlthough mitral valve replacement (MVR) is no longer the surgical
Surgery for Acquired Cardiovascular Disease Ruel et al Late incidence and predictors of persistent or recurrent heart failure in patients with mitral prosthetic valves Marc Ruel, MD, MPH a,b Fraser D.
More informationMechanical Tricuspid Valve Replacement Is Not Superior in Patients Younger Than 65 Years Who Need Long-Term Anticoagulation
Mechanical Tricuspid Valve Replacement Is Not Superior in Patients Younger Than 65 Years Who Need Long-Term Anticoagulation Ho Young Hwang, MD, PhD, Kyung-Hwan Kim, MD, PhD, Ki-Bong Kim, MD, PhD, and Hyuk
More informationReoperation for Bioprosthetic Mitral Structural Failure: Risk Assessment
Reoperation for Bioprosthetic Mitral Structural Failure: Risk Assessment W.R.E. Jamieson, MD; L.H. Burr, MD; R.T. Miyagishima, MD; M.T. Janusz, MD; G.J. Fradet, MD; S.V. Lichtenstein, MD; H. Ling, MD Background
More informationT sors in the following aspects: the porcine aortic valve
Clinical and Hemodynamic Assessment of the Hancock I1 Bioprosthesis Tirone E. David, MD, Susan Armstrong, MSc, and Zhao Sun, MA Division of Cardiovascular Surgery, The Toronto Hospital and University of
More informationP have been used for mitral and aortic valve replacement
A -Year Comparison of Mitral Valve Replacement With Carpentier-Edwards and Hancock Porcine Bioprostheses P. Perier, MD, A. Deloche, MD, S. Chauvaud, MD, J. C. Chachques, MD, J. Relland, MD, J. N. Fabiani,
More informationKinsing Ko, Thom de Kroon, Najim Kaoui, Bart van Putte, Nabil Saouti. St. Antonius Hospital, Nieuwegein, The Netherlands
Minimal Invasive Mitral Valve Surgery After Previous Sternotomy Without Aortic Clamping: Short- and Long Term Results of a Single Surgeon Single Institution Kinsing Ko, Thom de Kroon, Najim Kaoui, Bart
More informationQuality Outcomes Mitral Valve Repair
Quality Outcomes Mitral Valve Repair Moving Beyond Reoperation Rakesh M. Suri, D.Phil. Professor of Surgery 2015 MFMER 3431548-1 Disclosure Mayo Clinic Division of Cardiovascular Surgery Research funding
More informationClinical material and methods. Copyright by ICR Publishers 2003
Fourteen Years Experience with the CarboMedics Valve in Young Adults with Aortic Valve Disease Jan Aagaard 1, Jens Tingleff 2, Per V. Andersen 1, Christel N. Hansen 2 1 Department of Cardio-Thoracic and
More informationVALVE REPAIR VERSUS REPLACEMENT FOR MITRAL INSUFFICIENCY: WHEN IS A MECHANICAL VALVE STILL INDICATED?
VALVE REPAIR VERSUS REPLACEMENT FOR MITRAL INSUFFICIENCY: WHEN IS A MECHANICAL VALVE STILL INDICATED? Eugene A. Grossi, MD Aubrey C. Galloway, MD Jeffrey S. Miller, MD Greg H. Ribakove, MD Alfred T. Culliford,
More informationDepartment of Cardiothoracic Surgery, Heart and Lung Center, Lund University Hospital, Lund, Sweden
Long-Term Outcome of the Mitroflow Pericardial Bioprosthesis in the Elderly after Aortic Valve Replacement Johan Sjögren, Tomas Gudbjartsson, Lars I. Thulin Department of Cardiothoracic Surgery, Heart
More informationReconstruction of the intervalvular fibrous body during aortic and
Aortic and mitral valve replacement with reconstruction of the intervalvular fibrous body: An analysis of clinical outcomes Nilto C. De Oliveira, MD Tirone E. David, MD Susan Armstrong, MSc Joan Ivanov,
More informationSimultaneous Aortic and Mitral Valve Replacement in Octogenarians: A Viable Option?
Simultaneous Aortic and Mitral Valve Replacement in Octogenarians: A Viable Option? Ariane Maleszka, MD,* Georg Kleikamp, MD, PhD,* Armin Zittermann, PhD, Maria R. G. Serrano, MD, and Reiner Koerfer, MD,
More informationClinical material and methods. Fukui Cardiovascular Center, Fukui, Japan
Mitral Valve Regurgitation after Atrial Septal Defect Repair in Adults Shohei Yoshida, Satoshi Numata, Yasushi Tsutsumi, Osamu Monta, Sachiko Yamazaki, Hiroyuki Seo, Takaaki Samura, Hirokazu Ohashi Fukui
More informationRepair or Replacement
Surgical intervention post MitraClip Device: Repair or Replacement Saudi Heart Association, February 21-24 Rüdiger Lange, MD, PhD Nicolo Piazza, MD, FRCPC, FESC German Heart Center, Munich, Germany Division
More informationMitral valve (MV) repair is preferred over replacement. Is Mitral Valve Repair Superior to Replacement in Elderly Patients?
Is Mitral Valve Superior to in Elderly Patients? Gorav Ailawadi, MD, Brian R. Swenson, MD, MS, Micah E. Girotti, BS, Leo M. Gazoni, MD, Benjamin B. Peeler, MD, John A. Kern, MD, Lynn M. Fedoruk, MD, and
More informationLong-term relative survival after primary heart valve replacement 1
European Journal of Cardio-thoracic Surgery 11 (1997) 81 91 Long-term relative survival after primary heart valve replacement 1 Abstract E. Ståhle a, *, P. Kvidal b, S.O. Nyström a, R. Bergström c a Department
More informationDivision of Cardiothoracic Surgery, University of Miami, Miller School of Medicine, and Jackson Memorial Hospital, Miami, Florida
Multiple Valve Surgery with Beating Heart Technique Marco Ricci, MD, Francisco Igor B. Macedo, MD, Maria R. Suarez, MD, Michael Brown, CCP, Julia Alba, MD, and Tomas A. Salerno, MD Division of Cardiothoracic
More informationA 20-year experience of 1712 patients with the Biocor porcine bioprosthesis
Acquired Cardiovascular Disease Mykén and Bech-Hansen A 2-year experience of 1712 patients with the Biocor porcine bioprosthesis Pia S. U. Mykén, MD, PhD, a and Odd Bech-Hansen, MD, PhD b Objective: The
More informationAnn Thorac Cardiovasc Surg 2015; 21: Online April 18, 2014 doi: /atcs.oa Original Article
Ann Thorac Cardiovasc Surg 2015; 21: 53 58 Online April 18, 2014 doi: 10.5761/atcs.oa.13-00364 Original Article The Impact of Preoperative and Postoperative Pulmonary Hypertension on Long-Term Surgical
More informationBicuspid aortic root spared during ascending aorta surgery: an update of long-term results
Short Communication Bicuspid aortic root spared during ascending aorta surgery: an update of long-term results Marco Russo, Guglielmo Saitto, Paolo Nardi, Fabio Bertoldo, Carlo Bassano, Antonio Scafuri,
More informationThe Ross Procedure: Outcomes at 20 Years
The Ross Procedure: Outcomes at 20 Years Tirone David Carolyn David Anna Woo Cedric Manlhiot University of Toronto Conflict of Interest None The Ross Procedure 1990 to 2004 212 patients: 66% 34% Mean age:
More informationThe CarboMedics prosthetic valve (Sulzer CarboMedics,
Long-Term Result of 1144 CarboMedics Mechanical Valve Implantations Chang Hyun Kang, MD, Hyuk Ahn, MD, Kyung Hwan Kim, MD, and Ki-Bong Kim, MD Department of Thoracic and Cardiovascular Surgery, Seoul National
More informationExpanding Relevance of Aortic Valve Repair Is Earlier Operation Indicated?
Expanding Relevance of Aortic Valve Repair Is Earlier Operation Indicated? RM Suri, V Sharma, JA Dearani, HM Burkhart, RC Daly, LD Joyce, HV Schaff Division of Cardiovascular Surgery, Mayo Clinic, Rochester,
More informationMedtronic Mosaic porcine bioprosthesis: Assessment of 12-year performance
Medtronic Mosaic porcine bioprosthesis: Assessment of 12-year performance W. R. Eric Jamieson, MD, a Friedrich-Christian Riess, MD, b Peter J. Raudkivi, MD, c Jacques Metras, MD, d Edward F. G. Busse,
More informationContemporary outcomes for surgical mitral valve repair: A benchmark for evaluating emerging mitral valve technology
Contemporary outcomes for surgical mitral valve repair: A benchmark for evaluating emerging mitral valve technology Damien J. LaPar, MD, MSc, Daniel P. Mulloy, MD, Ivan K. Crosby, MBBS, D. Scott Lim, MD,
More informationSurgical AVR: Are there any contraindications? Pyowon Park Samsung Medical Center Seoul, Korea
Surgical AVR: Are there any contraindications? Pyowon Park Samsung Medical Center Seoul, Korea Contents Decision making in surgical AVR in old age Clinical results of AVR with tissue valve Impact of 19mm
More informationBall Valve (Smeloff-Cutter) Aortic Valve Replacement Without Anticoagulation
Ball Valve (Smeloff-Cutter) Aortic Valve Replacement Without Anticoagulation Begonia Gometza, MD, and Carlos M. G. Duran, MD, PhD Department of Cardiovascular Diseases, King Faisal Specialist Hospital
More informationThe Edge-to-Edge Technique f For Barlow's Disease
The Edge-to-Edge Technique f For Barlow's Disease Ottavio Alfieri, Michele De Bonis, Elisabetta Lapenna, Francesco Maisano, Lucia Torracca, Giovanni La Canna. Department of Cardiac Surgery, San Raffaele
More informationClinical material and methods. Copyright by ICR Publishers 2007
16847_JHVD_Biancari_3197_(116-121)_r1:Layout 1 21/3/07 17:07 Page 116 Predicting Immediate and Late Outcome after Surgery for Mitral Valve Regurgitation with EuroSCORE Jouni Heikkinen, Fausto Biancari,
More informationIncidence of prosthesis-patient mismatch in patients receiving mitral Biocor porcine prosthetic valves
INTERVENTION/VALVULAR HEART DISEASE ORIGINAL ARTICLE Cardiology Journal 2016, Vol. 23, No. 2, 178 183 DOI: 10.5603/CJ.a2016.0011 Copyright 2016 Via Medica ISSN 1897 5593 Incidence of prosthesis-patient
More informationLong-Term Results With the Medtronic-Hall Valvular Prosthesis
Long-Term Results With the Medtronic-Hall Valvular Prosthesis Cary W. Akins, MD Cardiac Surgical Unit, Massachusetts General Hospital, Boston, Massachusetts Background. Although more than 170,000 Medtronic-
More informationClosed mitral valvotomy was first reported by Cutler
Mitral Commissurotomy, a Technique Outdated? Long-Term Follow-up Over a Period of 35 Years Christian Detter, MD, Teddy Fischlein, MD, Christina Feldmeier, MD, Georg Nollert, MD, Hermann Reichenspurner,
More informationIsolated Mitral Valve Repair in Patients With Depressed Left Ventricular Function
Isolated Mitral Valve Repair in Patients With Depressed Left Ventricular Function Ashish S. Shah, MD, Steven A. Hannish, MD, Carmelo A. Milano, MD, and Donald D. Glower, MD Department of General and Thoracic
More information2017 Cardiovascular Symposium CARDIAC SURGERY UPDATE: SMALLER INCISIONS AND LESS COUMADIN DAVID L. SAINT, MD
2017 Cardiovascular Symposium CARDIAC SURGERY UPDATE: SMALLER INCISIONS AND LESS COUMADIN DAVID L. SAINT, MD David L Saint M.D. Tallahassee Memorial Hospital Southern Medical Group Division of Cardiothoracic
More informationDespite improvements in valve design, stroke remains a serious
Surgery for Acquired Cardiovascular Disease Bando et al Early and late stroke after mitral valve replacement with a mechanical prosthesis: Risk factor analysis of a 24-year experience Ko Bando, MD a Junjiro
More informationTen percent of patients with valvular heart disease have involvement
Surgery for Acquired Cardiovascular Disease Gillinov et al Mitral valve repair with aortic valve replacement is superior to double valve replacement A. Marc Gillinov, MD a Eugene H. Blackstone, MD a,b
More informationAtrial fibrillation (AF) is associated with increased morbidity
Ablation of Atrial Fibrillation with Concomitant Surgery Edward G. Soltesz, MD, MPH, and A. Marc Gillinov, MD Atrial fibrillation (AF) is associated with increased morbidity and mortality in coronary artery
More informationWhich Type of Secondary Tricuspid Regurgitation Accompanying Mitral Valve Disease Should Be Surgically Treated?
Ann Thorac Cardiovasc Surg 2013; 19: 428 434 Online January 31, 2013 doi: 10.5761/atcs.oa.12.01929 Original Article Which Type of Secondary Tricuspid Regurgitation Accompanying Mitral Valve Disease Should
More informationThe CarboMedics bileaflet prosthetic heart was introduced
The CarboMedics Valve: Experience With 1,049 Implants José M. Bernal, MD, José M. Rabasa, MD, Francisco Gutierrez-Garcia, MD, Carlos Morales, MD, J. Francisco Nistal, MD, and José M. Revuelta, MD Department
More informationEffect of Valve Suture Technique on Incidence of Paraprosthetic Regurgitation and 10-Year Survival
Effect of Valve Suture Technique on Incidence of Paraprosthetic Regurgitation and 10-Year Survival Sukumaran K. Nair, FRCS (C Th), Gauraang Bhatnagar, MBBS, Oswaldo Valencia, MD, and Venkatachalam Chandrasekaran,
More informationRheumatic fever and rheumatic heart disease still remain a. The Rheumatic Mitral Valve and Repair Techniques in Children. Afksendiyos Kalangos
The Rheumatic Mitral Valve and Repair Techniques in Children Afksendiyos Kalangos The mitral valve is the most commonly affected valve in acute and chronic rheumatic heart disease in the first and second
More informationDepartment of Cardiac Surgery, Trousseau University Hospital, Tours, France
Risk Factors for Valve-Related Complications after Mechanical Heart Valve Replacement in 505 Patients with Long-Term Follow Up Thierry Bourguignon, Eric Bergöend, Alain Mirza, Grégoire Ayegnon, Paul Neville,
More informationSince 1990, there has been a steady increase in cardiac
Outcomes of Patients Undergoing Concomitant Aortic and Mitral Valve Surgery in Northern New England Bruce J. Leavitt, MD; Yvon R. Baribeau, MD; Anthony W. DiScipio, MD; Cathy S. Ross, MS; Reed D. Quinn,
More informationChairman and O. Wayne Isom Professor Department of Cardiothoracic Surgery Weill Cornell Medicine
Leonard N. Girardi, M.D. Chairman and O. Wayne Isom Professor Department of Cardiothoracic Surgery Weill Cornell Medicine New York, New York Houston Aortic Symposium Houston, Texas February 23, 2017 weill.cornell.edu
More informationProf. Patrizio LANCELLOTTI, MD, PhD Heart Valve Clinic, University of Liège, CHU Sart Tilman, Liège, BELGIUM
The Patient with Aortic Stenosis and Mitral Regurgitation Prof. Patrizio LANCELLOTTI, MD, PhD Heart Valve Clinic, University of Liège, CHU Sart Tilman, Liège, BELGIUM Aortic Stenosis + Mitral Regurgitation?
More informationBasic principles of Rheumatic mitral valve Repair
Basic principles of Rheumatic mitral valve Repair Prof. Gebrine El Khoury, MD DEPARTMENT OF CARDIOVASCULAR AND THORACIC SURGERY ST. LUC HOSPITAL - BRUSSELS, BELGIUM 1 Rheumatic MV disease MV repair confers
More informationCONTRIBUTION. Aortic valve replacement in young patients: long-term follow-up
CONTRIBUTION Aortic valve replacement in young patients: long-term follow-up DOUGLAS S. MOODIE, MD; USAMA HANHAN, MD; RICHARD STERBA, MD; DANIEL J. MURPHY, Jr, MD; ELIOT R. ROSENKRANZ, MD; ANDREA M. KOVACS,
More informationResults of Mitral Valve Replacement, with Special Reference to the Functional Tricuspid Insufficiency
Results of Mitral Valve Replacement, with Special Reference to the Functional Tricuspid Insufficiency Ken-ichi ASANO, M.D., Masahiko WASHIO, M.D., and Shoji EGUCHI, M.D. SUMMARY (1) Surgical results of
More informationMitral Valve Disease, When to Intervene
Mitral Valve Disease, When to Intervene Swedish Heart and Vascular Institute Ming Zhang MD PhD Interventional Cardiology Structure Heart Disease Conflict of Interest None Current ACC/AHA guideline Stages
More informationTSDA Boot Camp September 13-16, Introduction to Aortic Valve Surgery. George L. Hicks, Jr., MD
TSDA Boot Camp September 13-16, 2018 Introduction to Aortic Valve Surgery George L. Hicks, Jr., MD Aortic Valve Pathology and Treatment Valvular Aortic Stenosis in Adults Average Course (Post mortem data)
More informationAtrioventricular valve repair: The limits of operability
Atrioventricular valve repair: The limits of operability Francis Fynn-Thompson, MD Co-Director, Center for Airway Disorders Surgical Director, Pediatric Mechanical Support Program Surgical Director, Heart
More informationThe prevalence of permanent cardiac pacing after. Permanent Cardiac Pacing After a Cardiac Operation: Predicting the Use of Permanent Pacemakers
Permanent Cardiac Pacing After a Cardiac Operation: Predicting the Use of Permanent Pacemakers Richard S. Gordon, BSc, Joan Ivanov, MSc, Gideon Cohen, MD, and Anthony L. Ralph-Edwards, MD Division of Cardiovascular
More informationSURGICAL ABLATION OF ATRIAL FIBRILLATION DURING MITRAL VALVE SURGERY THE CARDIOTHORACIC SURGICAL TRIALS NETWORK
SURGICAL ABLATION OF ATRIAL FIBRILLATION DURING MITRAL VALVE SURGERY THE CARDIOTHORACIC SURGICAL TRIALS NETWORK Marc Gillinov, M.D. For the CTSN Investigators ACC Late Breaking Clinical Trials March 16,
More informationAspirin or Coumadin as the Drug of Choice
Aspirin or Coumadin as the Drug of Choice for Valve Replacement with Porcine Bioprosthesis L. Nufiez, M.D., M. Gil Aguado, M.D., D. Celemin, M.D., A. Iglesias, M.D., and J. L. Larrea, M.D. ABSTRACT Eight
More informationVery Long-Term Survival Implications of Heart Valve Replacement With Tissue Versus Mechanical Prostheses in Adults <60 Years of Age
Very Long-Term Survival Implications of Heart Valve Replacement With Versus Prostheses in Adults
More informationLong-Term Assessment of Mitral Valve Reconstruction With Resection of the Leaflets: Triangular and Quadrangular Resection
Long-Term Assessment of Mitral Valve Reconstruction With Resection of the Leaflets: Triangular and Quadrangular Resection Yoshimasa Sakamoto, MD, Kazuhiro Hashimoto, MD, Hiroshi Okuyama, MD, Shinichi Ishii,
More informationLate secondary TR after left sided heart disease correction: is it predictibale and preventable
Late secondary TR after left sided heart disease correction: is it predictibale and preventable Gilles D. Dreyfus Professor of Cardiothoracic surgery Nath J, et al. JACC 2004 PREDICT Incidence of secondary
More informationΧειρουργική Αντιμετώπιση της Ανεπάρκειας της Μιτροειδούς Βαλβίδας
Χειρουργική Αντιμετώπιση της Ανεπάρκειας της Μιτροειδούς Βαλβίδας Dr Χρήστος ΑΛΕΞΙΟΥ MD, PhD, FRCS(Glasgow), FRCS(CTh), CCST(UK) Consultant Cardiothoracic Surgeon Normal Mitral Valve Function Mitral Regurgitation
More informationMinimally Invasive Stand Alone Cox-Maze Procedure For Patients With Non-Paroxysmal Atrial Fibrillation
Minimally Invasive Stand Alone Cox-Maze Procedure For Patients With Non-Paroxysmal Atrial Fibrillation Niv Ad, MD Chief, Cardiac Surgery Inova Heart and Vascular Institute Disclosures Niv Ad: Medtronic
More informationThe risk-benefit ratio of mitral valve operation is
Degenerative Mitral Regurgitation: When Should We Operate? Malcolm J. R. Dalrymple-Hay, PhD, Mark Bryant, Richard A. Jones, MRCP, Stephen M. Langley, FRCS, Steven A. Livesey, FRCS, and James L. Monro,
More informationThe clinical experience reported in recent Western series has provided
Surgery for Acquired Cardiovascular Disease Yu et al Long-term evaluation of Carpentier-Edwards porcine bioprosthesis for rheumatic heart disease Hsi-Yu Yu, MD a Yi-Lwun Ho, MD b Shu-Hsun Chu, MD c Yih-Sharng
More informationInfluence of Atrial Fibrillation on Outcome Following Mitral Valve Repair
Influence of Atrial Fibrillation on Outcome Following Mitral Valve Repair Eric Lim, MBChB, MRCS; Clifford W. Barlow, DPhil, FRCS; A. Reza Hosseinpour, FRCS; Christopher Wisbey, BA; Kate Wilson, RN, BSc;
More informationValve Repair for Mitral Regurgitation Caused by Isolated Prolapse of the Posterior Leaflet
Valve Repair for Mitral Regurgitation Caused by Isolated Prolapse of the Posterior Leaflet Patrick Perier, MD, J/2rgen Stumpf, MD, Christian GStz, MD, Fitsoum Lakew, MD, Andr6 Schneider, MD, Bernd Clausnizer,
More informationNineteen-Millimeter Aortic St. Jude Medical Heart Valve Prosthesis: Up to Sixteen Years Follow-up
Nineteen-Millimeter Aortic St. Jude Medical Heart Valve Prosthesis: Up to Sixteen Years Follow-up Dilip Sawant, FRCS, Arun K. Singh, MD, William C. Feng, MD, Arthur A. Bert, MD, and Fred Rotenberg, MD
More informationSurgical repair techniques for IMR: future percutaneous options?
Surgical repair techniques for IMR: can this teach us about future percutaneous options? Genk - Belgium Prof. Dr. R. Dion KULeu Disclosure slide Robert A. Dion I disclose the following financial relationships:
More informationPrimary Tissue Valve Degeneration in Glutaraldehvde-Preserved Porcine Biomostheses: Hancock I Vekus Carpentier-Edwards at 4- to 7-Years Follow-up
Primary Tissue Valve Degeneration in Glutaraldehvde-Preserved Porcine Biomostheses: A Hancock I Vekus Edwards at 4- to 7-Years Follow-up Francisco Nistal, M.D., Edurne Artifiano, M.D., and Ignacio Gallo,
More informationSpotlight on valvular heart disease guidelines. Prosthetic heart valves. Bernard Iung Bichat Hospital, Paris Diderot University Paris, France
Spotlight on valvular heart disease guidelines. Prosthetic heart valves. Bernard Iung Bichat Hospital, Paris Diderot University Paris, France Faculty disclosure First name - last name I disclose the following
More informationInfluence of patient gender on mortality after aortic valve replacement for aortic stenosis
Influence of patient gender on mortality after aortic valve replacement for aortic stenosis Jennifer Higgins, MD, W. R. Eric Jamieson, MD, Osama Benhameid, MD, Jian Ye, MD, Anson Cheung, MD, Peter Skarsgard,
More informationLong-term Experience with the Bjork-Shiley Monostrut Tilting Disc Valve
J Korean Med Sci 2007; 22: 1060-4 ISSN 1011-8934 DOI: 10.3346/jkms.2007.22.6.1060 Copyright The Korean Academy of Medical Sciences Long-term Experience with the Bjork-Shiley Monostrut Tilting Disc Valve
More informationTwenty-year experience with the St Jude Medical mechanical valve prosthesis
Surgery for Acquired Cardiovascular Disease Ikonomidis et al Twenty-year experience with the St Jude Medical mechanical valve prosthesis John S. Ikonomidis, MD, PhD John M. Kratz, MD Arthur J. Crumbley
More informationDe Vega Annuloplasty for Functional Tricupsid Regurgitation: Concept of Tricuspid Valve Orifice Index to Optimize Tricuspid Valve Annular Reduction
ORIGINAL ARTICLE Cardiovascular Disorders http://dx.doi.org/10.3346/jkms.2013.28.12.1756 J Korean Med Sci 2013; 28: 1756-1761 De Vega Annuloplasty for Functional Tricupsid Regurgitation: Concept of Tricuspid
More informationMinimally Invasive Mitral Valve Repair: Indications and Approach
Minimally Invasive Mitral Valve Repair: Indications and Approach Juan P. Umaña, M.D. Chief Medical Officer Director, Cardiovascular Medicine FCI - Institute of Cardiology Bogota Colombia 1 Mitral Valve
More informationSurgical AF Ablation : Lesion Sets and Energy Sources. What are the data? Steven F Bolling, MD Cardiac Surgery University of Michigan
Surgical AF Ablation : Lesion Sets and Energy Sources What are the data? Steven F Bolling, MD Cardiac Surgery University of Michigan Disclosures Consultant/Advisory Board: Abbott, Edwards Lifesciences
More informationDegenerative mitral valve disease is the leading cause of
Recurrence of Mitral Valve Regurgitation After Mitral Valve Repair in Degenerative Valve Disease Willem Flameng, MD, PhD; Paul Herijgers, MD, PhD; Kris Bogaerts, MSc Background Durability assessment of
More informationMidterm Outcomes Using the Physio Ring in Mitral Valve Reconstruction: Experience in 492 Patients
Midterm Outcomes Using the Physio Ring in Mitral Valve Reconstruction: Experience in 492 Patients Kevin D. Accola, MD, Meredith L. Scott, MD, Paul A. Thompson, MD, George J. Palmer III, MD, Mark E. Sand,
More informationValve Disease. Valve Surgery. Total Volume. In 2016, Cleveland Clinic surgeons performed 3039 valve surgeries.
Valve Surgery Total Volume 1 1 Volume 35 3 5 15 1 5 1 13 1 N = 773 5 79 15 93 1 339 In 1, surgeons performed 339 valve surgeries. surgeons have implanted more than 1, bioprosthetic aortic valves since
More informationValve Disease. Valve Surgery. In 2015, Cleveland Clinic surgeons performed 2943 valve surgeries.
Valve Surgery 11 15 Volume 3 1 11 1 13 1 N = 1 773 5 79 15 93 In 15, surgeons performed 93 valve surgeries. surgeons have implanted more than 1,5 bioprosthetic aortic valves since the 199s, with excellent
More information